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A B S T R A C T
Bradykinin-potentiating peptides (BPPs) or proline-rich oligopeptides (PROs) isolated from the venom
glands of Bothrops jararaca (Bj) were the ﬁrst natural inhibitors of the angiotensin-converting enzyme
(ACE) described. Bj-PRO-5a (<EKWAP), a member of this structurally related peptide family, was
essential for the development of captopril, the ﬁrst site-directed ACE inhibitor used for the treatment of
human hypertension. Nowadays, more Bj-PROs have been identiﬁed with higher ACE inhibition potency
compared to Bj-PRO-5a. However, despite its modest inhibitory effect of ACE inhibition, Bj-PRO-5a
reveals strong bradykinin-potentiating activity, suggesting the participation of othermechanisms for this
peptide. In the present study, we have shown that Bj-PRO-5a induced nitric oxide (NO) production
depended on muscarinic acetylcholine receptor M1 subtype (mAchR-M1) and bradykinin B2 receptor
activation, as measured by a chemiluminescence assay using a NO analyzer. Intravital microscopy based
on transillumination ofmice cremastermuscle also showed that both bradykinin B2 receptor andmAchR-
M1 contributed to the vasodilatation induced by Bj-PRO-5a. Moreover, Bj-PRO-5a-mediated vasodilata-
tion was completely blocked in the presence of a NO synthase inhibitor. The importance of this work lies
in the deﬁnition of novel targets for Bj-PRO-5a in addition to ACE, the structural model for captopril
development.
 2011 Elsevier Inc.
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Bradykinin-potentiating peptides (BPPs) found in the venom
gland of the South American pit viper Bothrops jararaca are
typically proline-rich oligopeptides (PROs) composed of 5–14
aminoacid residues with a pyroglutamate and a proline residue inAbbreviations: ACE, angiotensin-converting enzyme; ASS, argininosuccinate
synthase; Bj, Bothrops jararaca; BK, bradykinin; BPPs, bradykinin-potentiating
peptides; Bj-PROs, proline-rich oligopeptides from the venom glands of Bothrops
jararaca venom glands; HEK, human embryonic kidney; CHO, Chinese hamster
ovarian; [Ca2+], iintracellular calcium concentration; eNOS, endothelial nitric oxide
synthase; L-NMMA, NG-methyl-L-arginine acetate salt; mAchR, muscarinic acetyl-
choline receptor; mAchR-M1, muscarinic acetylcholine receptor M1 subtype; NO,
nitric oxide; PLC-g, phospholipase C-g.
* Corresponding author at: Center for Applied Toxinology CAT/CEPID, Instituto
Butantan, Av. Vital Brasil 1500, Sa˜o Paulo, SP 05503-900, Brazil.
Tel.: +55 11 3726 1024; fax: +55 11 3726 1024.
E-mail address: claulameu@butantan.gov.br (C. Lameu).
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Open access under the Elsevier OA license.their N- and C-termini, respectively [1,2]. These peptides named as
Bj-PROs or Bj-BPPs were the ﬁrst naturally occurring angiotensin-
converting enzyme (ACE) inhibitors to be described [1]. The
pentapeptide Bj-PRO-5a, one of the ﬁrst BPPs, those sequence was
determined and produced by chemical synthesis, was shown to be
active in inhibiting angiotensin I conversion and bradykinin (BK)
degradation in rat lungs [3]. The work of Cushman et al. [4]
suggested that the C-terminal domain of this peptide as well as of
the related peptide Bj-PRO-9a speciﬁcally interacted with the
catalytic site of ACE. These pioneering studies resulted in the
development of the ﬁrst site-directed ACE inhibitor, named
Captopril, which as oral-administered drugs has been used in
humans since the 1980s for treatment of systemic arterial
hypertension [5,6].
Although the intensive characterization of Bj-PRO-5a as an
efﬁcient potentiating agent of BK effects [1,7,8], this peptide is not
a high-afﬁnity inhibitor of C-terminal active site of ACE [9]. In fact,
Bj-PRO-5a revealed much more afﬁnity for the N-terminus active
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formation of angiotensin II and to degrade BK [10,11], giving more
support to the suggestion of a potential existence of other targets
for Bj-PRO-5a action. Despite the enormous contribution of Bj-
PRO-mediated ACE inhibition on science and public health, we
have demonstrated that ACE inhibition does not fully explain
vasodilatation and anti-hypertensive actions exerted by Bj-PROs in
vivo [12–14]. In fact, we have recently shown that Bj-PRO-
promoted vasodilatation is not only due to a decrease of
angiotensin II formation and/or to the increase of BK concentration,
but it also involves nitric oxide (NO) production [13]. NO
principally participates in the regulation of local and systemic
vascular resistance and sodium balance and consequently in the
control of arterial pressure [15]. NO diffuses through smooth
muscles, where it activates guanylate cyclase, stimulating cGMP
production and therefore promoting blood vessel relaxation [16–
18]. In endothelium, NO originates from L-arginine by action of
endothelial NO synthase (eNOS), whose activity is supposed to
increase when cytosolic calcium levels ([Ca2+]i) are increased by
receptor activity [19–21]. Both BK B2 receptors and muscarinic
acetylcholine receptors (mAChRs) can induce [Ca2+]i transients
that results in eNOS activation and NO production [16,22].
In the present work, we have provided evidence that Bj-PRO-5a
increased NO production in human embryonic kidney (HEK293)
cells, which ismediated by BK B2 receptor as well as bymAChR-M1
activation. Bj-PRO-5a–induced mAChR-M1 activity was conﬁrmed
by [Ca2+]i measurements in Chinese hamster ovarian (CHO) cells
expressing recombinant rat mAChR-M1 (CHO-M1). Moreover,
intravital microscopy based on transillumination of mice cre-
master muscle revealed that both BK B2 receptor and mAchR-M1
contribute to the vasodilatation induced by Bj-PRO-5a in vivo, and
that this effect was completely blocked by the NO synthase
inhibitor L-NMMA.
2. Materials and methods
2.1. Synthesis and puriﬁcation of Bj-PRO-5a
Bj-PRO-5a (<EKWAP) was synthesized essentially as previously
described by Gomes et al. [23]. Brieﬂy, the synthesis of Bj-PRO-5a
was performed on an automated PSSM-8 peptide synthesizer
(Shimadzu Corp., Kyoto, Japan) by a stepwise solid-phase method
using N-9-ﬂuorenylmethoxycarbonyl (Fmoc) chemistry (Novabio-
chem-EMDChemicals, SanDiego, CA). Cleavage of the peptide from
the resin was achieved by treatment with a mixture of
triﬂuoroacetic acid (TFA)/1,2-ethanedithiol/ethyl methyl sulﬁde
for 2 h at room temperature. After removal of the resin by ﬁltration
and washing twice with tri-ﬂuoracetic acid (TFA), the crude
synthetic peptide was puriﬁed by preparative reversed-phase
high-performance liquid chromatography (HPLC) (Shimadzu
Corp.) on a YMC-Pack ODS column 20 mm  150 mm (YMC, Kyoto,
Japan), using a linear gradient from 3% to 20% CH3CN in 0.1% TFA, at
a ﬂow rate of 7 ml/min. Both, the purity and primary structure of
each synthetic peptide were conﬁrmed by analytical HPLC and
MALDI-TOF mass spectrometry (Amersham Biosciences, Uppsala,
Sweden). The sample was frozen in liquid nitrogen and then
freeze-dried (Edwards Freeze Dryer Super Modulyo Pirani 1001,
Thermo Fisher Scientiﬁc, Waltham, MA) for 48 h at 50 8C under
vacuum. Following this procedure [14], the counter ion TFA was
completely exchanged as determined mass spectrometry.
2.2. Animals
Experiments were performed using 12 male BALB/c mice (25–
30 g body weight), which were bred in animal care facility of the
Instituto Butantan (Sao Paulo, SP, Brazil). The animals had freeaccess to food and water and were submitted to a light/dark cycle
(12 h each) before the preparation for the experiments. All animals
were handled under ethical conditions according to international
rules of animal care, stated by the International Animal Welfare
Recommendations, and in accordance with the guidelines estab-
lished by our local institutional animal welfare committee
(CEUAIB/Instituto Butantan, protocol 653/09).
2.3. Cell culture
HEK293 (Human Embryonic Kidney 293) cells [ATCC No. CRL-
1573] were cultured in DMEM, supplemented with 10% fetal
bovine serum, 2 mM L-glutamine, 100mg/ml streptomycin sulfate
and 100 U/ml penicillin G. Wild type Chinese hamster ovarian
(CHO-K1) cells [ATCC No. CCL-61], as well as mAChR-M1
expressing CHO cells (CHO-M1) [ATCC No. CRL-1984] and
mAChR-M3 expressing CHO cells (CHO-M3) [ATCC No. CRL-
1981], were all cultured in F-12 medium supplemented with
10% fetal bovine serum, 100mg/ml streptomycin sulfate and
100 U/ml penicillin G. Geneticine (100mg/ml) was added to the
media of transfected cells for selection of mAchR expressing cells.
HEK293 and CHO cells were kept at 37 8C in 5% CO2 atmosphere.
The medium was changed after 12 h and then every three days.
2.4. Chemiluminescence assay for measurement of nitric oxide
products
For the NO quantiﬁcation, 1  106 HEK293 cells were placed on
6-wells plates with culture medium supplemented with fetal
bovine serum. After the period of cell adhesion, the culture
medium was replaced by medium without serum, adding to the
cell culture Bj-PRO-5a in the range ﬁnal concentration of 0.03–
3mM, for a period of 24 h. Then the culture medium was collected
and centrifuged at 90 g for 5 min to eliminate possible debris and
the supernatant was collected for analysis of nitrate. The cells were
lysed with RIPA buffer (50 mM Tris–HCl, pH 7.5, 150 mM NaCl,
Nonidet P-40 (NP-40) 1% sodium deoxycholate 0.5%, 0.1% SDS,
1 mM DTPA and 10 mM N-ethylmaleimide). Then, the cells were
incubated on ice for 30 min for cell lysis and then were centrifuged
for 15 min at 21,000  g and 4 8C. The methodology and
instrumentation for the measurements was as described by
Feelisch et al. [24]. The intracellular medium and extracellular
mediumwere directly injected into a vessel containing a saturated
solution of vanadium III chloride in 1 N HCl maintained at 90 8C.
Under these conditions, all nitric oxide-derived products (nitrate,
nitrite, nitrosothiol, nitrosamines, and iron-nitrosyl complexes)
were reduced and compared with those of standard solutions of
nitrate under the same experimental conditions.
2.5. Measurements of changes in free intracellular calcium
concentration ([Ca2+]i) measurements by microﬂuorimetry
Changes in [Ca2+]i were determined by microﬂuorimetry using
the FlexStation III (Molecular Devices Corp., Sunny Valley, CA),
following the same protocol described in Lameu et al. [14]. Brieﬂy,
cells were seeded a night before starting the experiment at a
density of 5  104 cells/well in 96-well black walled and clear
bottomed microplates, with 100 ml of cell culture medium per
well. Cells were incubated for 60 min at 37 8C with the FlexStation
Calcium Assay Kit (Molecular Devices Corp.) containing 2.5 mM
probenecid in a ﬁnal volume of 200 ml/well. Before and after
addition of Bj-PRO-5a, ﬂuorescence of samples was excited at
485 nm, and ﬂuorescence emission was detected at 525 nm.
Samples were read at 1.52 s intervals for 120 s with a total of 79
read-outs per well. Responses weremeasured at the peak intensity
of ﬂuorescence compared to baseline ﬂuorescence intensity.
Fig. 1. Dose-dependent induction of NO production by Bj-PRO-5a in HEK293 cells.
HEK293 cells were seeded into Petri dishes in appropriate medium and cultured for
24 h. Then, cells were incubated for 24 h periods in serum-free medium with
increased concentrations of Bj-PRO-5a. The medium was collected (extracellular
medium), and the cells were lysed with RIPA buffer to measure intracellular NO
products by a chemiluminescence assay. The shown data are expressed as mean
values  S.E. of three independent assays. *P < 0.05; **P < 0.01 or ***P < 0.001
compared to basal NO production by HEK293 cells.
Fig. 2. Involvement of BK B2 receptors and mAChRs in Bj-PRO-5a-induced NO
production by HEK293 cells. NO production by HEK293 cells was determined
following treatment for 24 h with 0.3 (M Bj-PRO-5a in the absence or presence of
speciﬁc antagonists of the BK B2 receptor (1 (M HOE-140), the mAChR-M1 (1 mM
pirenzepine), mAChR-M2 (100 (M gallamine) and mAChR-M3 (10 (M 4-DAMP). NO
peak values obtained in the presence of Bj-PRO-5a alone were considered as 100%
activation. The shown data are expressed asmean values  S.E. of three independent
assays. **P < 0.01 or ***P < 0.001 compared to the control measurements in the
presence of Bj-PRO-5a alone.
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The dynamics of alterations in the microcirculatory network
were determined using intravital microscopy by trans-illumina-
tion of the mice cremaster muscle after intravenous application of
the peptide (71 nmol/Kg) dissolved in saline sterile. Administra-
tion of the same amount of sterile saline was used as a control.
Before beginning the experiments, mice were injected with a
muscle relaxant drug (0.4% Xilazin) (Coopazine1, Schering-Plough)
and then anaesthetized with 0.2 g/kg chloral hydrate and the
cremaster muscle was exposed for microscopic examination in situ
as previously described [25,26].
The animals were maintained on a special designed board
controlled thermostatically at 37 8C, which included a transparent
platform on which the trans-illuminated tissue was placed
arteriolar diameter was measured in different times after peptide
injection (5, 10, 15, 20, 25 and 35 min). The study of the
microvascular system of trans-illuminated tissue was performed
using an optical microscope (Axiolab, Carl Zeiss, Oberkochen,
Germany) coupled to photographic camera (AxioCam ICc1) using a
10/0.3 longitudinal distance objective/numeric aperture and 1.6
optovar.
2.7. Statistical analysis
Comparisons were made by one-way analysis of variance
(ANOVA) with the Bonferroni post-test using GraphPad Prism 5.0
software (GraphPad Software Inc., San Diego, CA). The criteria for
statistical signiﬁcance were set at *P < 0.05; **P < 0.01 and
***P < 0.001.
3. Results
3.1. Bj-PRO-5a-induced NO production in HEK293 cells
Previous work has suggested that Bj-PRO-promoted vasodila-
tation does not only result from ACE inhibition [12,14], but also
involves sustained NO production [13]. Therefore, aiming to
measure the sustained NO production in HEK293 cells induced by
Bj-PRO-5a, NOx (nitrate, nitrite, nitrosothiol, nitrosamines, and
iron-nitrosyl complexes) levels in total (intracellular and extracel-
lular) media were determined following 24 h of incubation with
several concentrations of this peptide. NOx concentration in
HEK293 cells was increased in the presence of 0.3–3mM Bj-
PRO-5a dose-dependently. Maximal stimulations of 137%
(13.68  1.84 nmol/106 cells) over basal values (4.75  0.68 nmol/
106 cells) were obtained in the presence of 3 mM Bj-PRO-5a (Fig. 1).
HEK293 cells express functional BK B2 receptors as well as
mAChRs [27,28], and both play a role in the NO production of the
endothelium. NOx levels were also determined in cells pretreated
with HOE-140, an antagonists of BK B2 receptors [29], or with
pirenzepine, gallamine or 4-DAMP being at the concentration used
speciﬁc inhibitors of mAChRs subtypes M1, M2 orM3, respectively
[30], prior to addition of 0.3 mM Bj-PRO-5a. The used concentra-
tions of the membrane receptor antagonists were sufﬁcient to
inhibit subtype-speciﬁc receptor responses elicited by 1mM BK or
50 mMmuscarine (data not shown). Inhibition of BK B2 receptor or
mAchR-M1 activity resulted in a reduction of Bj-PRO-5a-induced
NO production by 40% and 60%, respectively (Fig. 2).
3.2. Bj-PRO-5a-induced [Ca2+]i transients in HEK293 and CHO-M1
cells
Bj-PRO-5a-induced [Ca2+]i transients were measured by micro-
ﬂuorimetry after stimulation of HEK293 cells, showing an effect
dose–response curves (Fig. 3A). The Bj-PRO-5a showed potency(pD2 values) of 7.93  0.12. Moreover, we observed that the increase
of [Ca2+]i was instantaneous and transient, i.e., the maximal peak
response of [Ca2+]i was reached immediately after the stimulation of
HEK293 cells with the Bj-PRO-5a, returning to the baseline values
within 120 s (data not shown). Although, Bj-PRO-5a has been
primarily described as a potentiate of BK, the Bj-PRO-5a-induced
[Ca2+]i transients are not mediated by BK B2 receptor, since
pretreatment of HEK293 cells with a speciﬁc antagonist of this
receptor, HOE-140, did not affect its response, showing pD2 values of
8.05  0.21 similar to that obtained by Bj-PRO-5a in HEK293 cells
without any pretreatment (Fig. 3A). These [Ca2+]i transients
contributing to NOS activation may be due to mAchR-M1 activation,
since Bj-PRO-5a-promoted [Ca2+]i transients were completely inhib-
Fig. 3. Bj-PRO-5a-induced [Ca2+]i elevations in HEK293 and CHO cells expressing recombinant rat m1AChR. Changes of maximal peak heights of [Ca
2+]i responses induced by
several concentrations of Bj-PRO-5a (0.003–1 mM)weremeasured in (A) HEK293 cells and HEK293 cells pretreatedwith 1mMHOE140 or 1 mMpirenzepine for 30 min prior
to addition of Bj-PRO-5a and (B) CHO-K1 cells; CHO-K1 cells expressing recombinant mAChR-M1 (CHO-M1), CHO-K1 cells expressing mAChR-M3 (CHO-M3) receptor by
microﬂuorimetry using FlexStation III (Molecular Devices Corp.). The data shown are mean values  S.E. of three independent assays.
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subtype receptor, pirenzepine (Fig. 3A). Bj-PRO-5a induced [Ca2+]I
elevations observed in CHO-M1were never detected in CHO-M3 or in
wild-type CHO-K1 cells (Fig. 3B). Bj-PRO-5a effects on the mobiliza-
tion of the [Ca2+]i in CHO-M1 cells revealed pD2 values of 7.54  0.14.
3.3. Bj-PRO-5a-promoted vasodilatation in the microvascular system
of BALB/c mice
Based on the observation of NO production in HEK293 cells in
the presence of Bj-PRO-5a, we analyzed the effect of the peptide in
the microvasular system of BALB/c mice. For this, intravital
microscopy of mice cremaster muscle was performed. These
experiments revealed that 71 nmol/Kg of Bj-PRO-5a promoted
vasodilatation in the arterioles medium caliber, showing discrete
effect after 5 min of peptide administration and reaching the
maximum effect (change of 49% in diameter) at 25 min (Fig. 4).
Moreover, the Bj-PRO-5a-provoked vasodilator action signiﬁcantly
decreased when the animals were pretreated with 100 nmol/Kg of
HOE-140 and 175 nmol/Kg of pirenzepine (Fig. 5), but was totallyFig. 4. Bj-PRO-5a produced relaxation of blood vessels of the Balb-c mouse observed b
percentages of vasodilatation in different times (5, 10, 15, 20, 25 and 30 min) after intrav
muscle before (0 min) and after 20 min of intravenous application of 71 nmol/Kg Bj-PRO
shown are mean values  S.E. of three independent experiments.abolished by pretreatment with 100 mg/Kg NG-methyl-L-arginine
acetate salt (L-NMMA), a speciﬁc inhibitor of NOS [31].
4. Discussion
Recently published works have suggested that the mechanism
responsible for the enhancement of BK activity by Bj-PROs cannot
be entirely explained by the inhibition of ACE enzymatic activity
[9,23,32,33]. Furthermore, ACE inhibition as the only explanation
for the antihypertensive effects caused by inhibitory molecules of
this enzyme has been challenged in the literature [34–38]. Thus,
the hypothesis was raised that each Bj-PRO might act through
distinct mechanism of action, probably involving different target
proteins [9,23]. Recently, our group demonstrated that Bj-PRO-7a
is a mAchR-M1 agonist [39], and Bj-PRO-10c action involves
argininosuccinate synthase (ASS) activation, a key enzyme to
provide substrate for NOS [13].
Nitric oxide is a key-mediator for the maintenance of integrity
and functionality of the endothelium including regulation of the
vascular tonus, prevention of leukocyte ﬁltration, thrombusy intravital micrographs of cremaster muscle. (A) Representative graph showing
enous application of 71 nmol/Kg Bj-PRO-5a. (B) Intravital micrographs of cremaster
-5a. Microphotographs were obtained from computer digitalized images. The data
Fig. 5. Bj-PRO-5a-provoked vasodilatation effect is mediated by NO production following BK B2 receptor and m1AChR activation. The ﬁgure shows percentages of
vasodilatation at different times after intravenous application of 71 nmol/Kg Bj-PRO-5a (white bars) and after administration of Bj-PRO-5a inmouse pretreatedwith 100 mg/
Kg L-NMMA, a speciﬁc inhibitor of NOS (black bars) or 175 nmol/Kg pirenzepine or 100 nmol/Kg HOE-140, which are m1AChR and BK B2 receptor antagonists, respectively.
The data shown are mean values  S.E. of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to control (percentage of Bj-PRO-5a-promoved
vasodilatation).
K.L.P. Morais et al. / Biochemical Pharmacology 81 (2011) 736–742740formation and angiogenesis [40]. Although, Bj-PRO-5a is not an ASS
activator (data not shown), this peptide also induced NO
production in a dose-dependent manner. Attempting to elucidate
molecular mechanisms of Bj-PRO-5a-induced NO production, we
provide evidence that BK B2 receptors and mAchR-M1 affect NO
production produced by Bj-PRO-5a in HEK293 cells, since in the
presence of speciﬁc antagonists of these receptors Bj-PRO-5a-
evokedNO accumulationwas reduced to 40% and 60% of respective
control values found in the absence of these inhibitors.
Stimulation of BK B2 receptors by BK leads to transients
increases in [Ca2+]i. This BK-induced [Ca
2+]i elevation activates NOS
for NO generation [16,41]. Many other receptors, when activated,
generate intracellular signals to induce NO production; among
these are the mAchR-M1 and mAchR-M3, which are also involved
in blood pressure regulation [22,42–44]. Muscarinic AChR-M1-
promoted NO production is also known to depend on [Ca2+]i
mobilization involving formation of cGMP by soluble guanylate
cyclase [45]. The signal transduction exerted by the mAchR-M1
involves Gq protein activation followed by participation of various
signaling molecules including phospholipases, mitogen-activated
protein kinases and NOS and result in physiological actions
depending on the localization of the receptor [46]. In the
endothelium, for instance, mAchR-M1-mediated increases in
[Ca2+]i provokes eNOS activation and NO production for promotion
of vasodilatation. Regulation of vascular tonus by the mAchR-M1
produced vasodilatation effect was described by Ryberg et al. [22],
who showed that the mAChR-M1 is expressed in the endothelium,
and stimulation of this receptor promotes NO-dependent relaxa-
tion in arterial preparations from rat submandibula. In agreement
with the activation of mAchR-M1-speciﬁc signal transduction,
vasodilatation induced by Bj-PRO-5a in mouse microvasculature
was completely blocked by a speciﬁc NOS inhibitor, L-NMMA.
Furthermore, this vasodilatation effect was compromised when
animals had been pretreated BK B2 receptor or mAchR-M1
antagonists, conﬁrming the participation of these receptors in
Bj-PRO-5a-mediated actions.
The participation of the BK B2 receptor in Bj-PRO-5a-promoted
actions leading to NO production might result from BK accumula-
tion following ACE inhibition; however Bj-PRO-5a is a very modestinhibitor of this enzyme important for BK degradation [9,47].
Moreover, ACE is absent in HEK293 cells [48,49], and the
endogenous expression of the BK B2 receptor and ACE is very
low or absent in CHO cells [50]. Therefore, the Bj-PRO-5a
mechanism of action may not involve a direct action on BK B2
receptors and/or BK accumulation. In view of that and having in
mind that Bj-PRO-5a potentiates BK-induced effects [9,23], our
data could be explained by a Bj-PRO-5a-promoted crosstalk
between BK B2 receptors and mAChR-M1 expressed in the same
cell sharing signaling pathways and resulting in a synergistic
regulation of NO signaling. This synergistic action should be
independent from oligomerization [51], since Bj-PRO-5a-induced
[Ca2+]i mobilization was not observed in HEK293 cells pretreated
with an antagonist of BK B2 receptors, but was completely
abolished by an antagonist ofmAchR-M1.Moreover, Bj-PRO-5a did
not exert effects on cells not expressing mAChR-M1, such as CHO-
K1 (wild type) cells and CHO-M3 cells (expressing recombinantM3
receptors), suggesting that Bj-PRO-5a is amAChR-M1 agonist, such
as Bj-PRO-7a [14,34]. Activation of mAChR-M1 is supposed to
activate a cross-talkwith the BK B2 receptor, thereby potentializing
BK-mediated effects [23] and producing vasodilatation in vivo.
We have also observed that the non-peptide ACE inhibitor,
captopril, does not induce [Ca2+]i mobilization in cells responsive
to Bj-PRO-5a, such as human neuroblastoma and HEK293 cells,
which express functional mAchR (data not shown). We might also
consider that non-peptide ACE inhibitors are usually dramatically
smaller than the peptide toxin, even when compared to Bj-PRO-5a
and, therefore, it would not be expected to observe similar docking
features [52,53]. In fact, as discussed in this work, Bj-PRO-5a does
not seem to act on ASS in the sameway as described for Bj-PRO-10c
[13].
Many studies have previously suggested different mechanisms
of BK-potentiation by ACE inhibitors [48,50,54]. Marcic et al.
demonstrated that enalaprilat preserved the activity of the high-
afﬁnity BK B2 receptor by abolishing of ligand-induced receptor
desensitization and decreasing receptor endocytosis rates by
inducing crosstalk between ACE and the receptor [54]. Another
work performed by Bachvarov et al. showed that captopril may
limit BK B2 receptor independently from ACE involvement [48].
K.L.P. Morais et al. / Biochemical Pharmacology 81 (2011) 736–742 741The conclusions of our paper are in agreements with those actions
of ACE inhibitors of the cited previous and contribute to the
elucidation of involved mechanisms. In addition to the identiﬁca-
tion of a novel putative target underlying the vasodilatation
promoted by the Bj-PRO-5a, possible future therapeutic applica-
tions of this peptide are not limited to the treatment of
cardiovascular diseases. Much effort has been undertaken in the
search of mAchR-M1 agonists to treat cognitive disorders
including the Alzheimer disease [55–57], since the observed
cognitive deﬁciencies have been shown to correlatewith the loss of
mAchR-M1 functionality [58]. Furthermore, this peptide could
become an important tool to study cross-talk mechanisms
between the two Gq-protein coupled metabotropic receptors.
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